Drug intelligence / Profile preview

ABI-107

Development stage: Preclinical
Lead developer: Avirmax Biopharma
Modality: Gene Therapies
Administration: Intravitreal

Overview

ABI-107 is a preclinical-stage adeno-associated virus (AAV) gene therapy candidate developed by Avirmax Biopharma for the treatment of inflammatory and neovascular ocular diseases. The program is designed to address conditions including non-infectious uveitis (NIU), uveal choroidal neovascularization (uvCNV), and uveal macular edema (UMO). By utilizing an engineered AAV vector to deliver a therapeutic transgene directly to ocular tissues, ABI-107 aims to provide durable expression of therapeutic proteins, potentially offering a long-term alternative to the frequent intravitreal injections required by current standard-of-care biologics.

Targets

VEGFB (Vascular endothelial growth factor B)VEGFA (Vascular endothelial growth factor A)PGF (Placental Growth Factor)

Beyond the preview

Go deeper on ABI-107.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABI-107.

Explore the full profile